---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013622"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:24:28.106786+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial

## Summary
- Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.
- R&D expenses rose $3.2M to $10.4M due to clinical programs for PF614 and PF614-MPAR.
- Enrolled first patient in Phase 3 trial (PF614-301) for moderate-to-severe post-surgical pain.
- FDA supports streamlined 505(b)(2) pathway for PF614-MPAR with overdose-protection labeling.
- USPTO allowed new MPAR patent covering composition-of-matter and method-of-use claims through 2042.

## SEC filing metadata
- accession: 0001493152-26-013622
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/0001493152-26-013622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013622
- JSON: https://secwatch.observer/filing/0001493152-26-013622.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.